Replies to post #791 on Versartis, Inc. (VSAR)

[longx]

Of course there is a possibility of reverse takeover, too. But with all the progress have been made so far as described under the Corporate Update session in the E/R which can be viewed via this link ), and we all know that Versartis's Somavaratan does work (as described in this article ), it's just that the drug is as effective as Pfizer's Genotropin, but Somavaratan is designed for bi-weekly treatment while Pfizer's Genotropin required daily injection, and Ascendis's TransCon designed for weekly treatment, and also Somavaratan can be stored at room temperature. Given all of this, what would be best scenario for maximizing shareholders value? THX!

[TheFinalCD]

Versartis Enters into Merger Agreement with Aravive Biologics to Form a Clinical-Stage Biopharmaceutical Company Advancing Innovative Oncology Therapeutics

http://aravive.com/pipeline/